Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $248

Benzinga Newsdesk www.benzinga.com Positive 84.3%

Neg 0% Neu 0% Pos 84.3%

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $245 to $248.